Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries
- 20 April 2026
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (4) , e70381
Abstract
Background: Prescription stimulant use among the United States' (US) older adult population is increasing, yet little is known about the cardiovascular safety profiles of the two major prescription stimulant classes, methylphenidate (MPD) and amphetamine (AMP). Objective: To compare the hazard of major adverse cardiovascular (CV) events between new users of prescription MPD and AMP products in US older adults. Methods: We employed a new user comparative safety study from a 5% random sample of fee‐for‐service Medicare beneficiaries. Continuously enrolled beneficiaries (Parts A/B/D) aged ≥ 66 years who initiated MPD or AMP (1/1/17–12/31/21) were included. We required a 1‐year washout before the first prescription claim (index date) and excluded those with contraindications based on diagnosis codes. The primary outcome was incident modified 4‐Point Major Adverse Cardiovascular Event (4‐P MACE), including acute myocardial infarction, stroke or transient ischemic attack, ventricular arrhythmia, or all‐cause mortality; secondary outcomes included all‐cause mortality and CV events (all MACE excluding death). We used a 1‐year follow up after index date that was censored at change in insurance coverage, therapeutic switch, addition of the comparator drug, or end of the study (12/31/21). Confounders included demographics, healthcare utilization indicators, comorbidities, and other medications. We used trimmed propensity scores (PS) to create stabilized inverse probability of treatment weights (IPTW) and Cox proportional hazard regression to estimate the effect of MPD vs. AMP initiation on the first occurrence of 4‐P MACE. Results: We identified 2526 Medicare beneficiaries initiating MPD ( N = 1340, mean [SD] age = 76.7 [7.4] years, 54.3% female sex) or AMP ( N = 1186, mean [SD] age = 72.3 [5.4] years, 60.6% female sex). After PS trimming and applying IPTW, the groups were well‐balanced based on absolute standardized mean differences. During 2021.6 person‐years follow up (MPD [1009.9 years] vs. AMP [1011.8 years]), 339 4‐P MACE events occurred (MPD [ N = 280] vs. AMP [ N = 59]), of which 225 were deaths (MPD [ N = 192] vs. AMP [ N = 33]), and 114 were CV events (MPD [ N = 88] vs. AMP [ N = 26]). In the primary analysis, MPD vs. AMP initiation was associated with an increased risk of 4‐P MACE (HR = 1.73, 95% CI [1.36, 2.19]). The secondary analysis showed a statistically significant increased risk of all‐cause mortality (HR = 2.20, 95% CI [1.62, 3.00]), but not adverse CV events (HR = 1.14, 95% CI [0.77, 1.67]). Conclusions: Initiation of MPD vs. AMP among older adults was associated with an increase in the hazard of 4‐P MACE. Secondary analysis suggested that this increase was driven by all‐cause mortality as opposed to adverse CV events.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysiseClinicalMedicine, 2023
- Target Trial EmulationJAMA, 2022
- HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task forcePharmacoepidemiology and Drug Safety, 2022
- Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: An observational cohort studyeClinicalMedicine, 2022
- Assessment of Stimulant Use and Cardiovascular Event Risks Among Older AdultsJAMA Network Open, 2021
- Immortal Time Bias in Observational StudiesJAMA, 2021
- Time‐related biases in pharmacoepidemiologyPharmacoepidemiology and Drug Safety, 2020
- FDA Drug Safety Communications: A Narrative Review and Clinical Considerations for Older AdultsThe American Journal of Geriatric Pharmacotherapy, 2012
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamineSynapse, 2005